Physician profile
Gregory E Chambon
NPI 1861489205
$1,177.55
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $142 · 2021: $191 · 2022: $397 · 2023: $302 · 2024: $39.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.64 | 2021-2024 | Ubrelvy, Vraylar, Botox |
| Allergan, INC. | $183.06 | 2020-2022 | |
| Novo Nordisk INC | $167.28 | 2019-2023 | Rybelsus, Ozempic |
| Antares Pharma, INC. | $116.03 | 2019-2022 | |
| Lilly USA, LLC | $53.97 | 2022 | |
| Shire North American Group INC | $37.31 | 2019 | |
| Hologic Sales and Service, LLC | $34.55 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $33.50 | 2023-2024 | |
| Glaxosmithkline, LLC. | $28.44 | 2020-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $23.85 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $22.71 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $19.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.91 | 2020 | |
| Amarin Pharma, INC. | $14.53 | 2020 | |
| Dexcom, INC. | $12.28 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $8.35 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Chambon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.